About 35% of adults, or 86 million, have high cholesterol above 200 mg/dL Enlicitide, an oral pill, reduces LDL cholesterol by up to 60% in a phase 3 trial Enlicitide inhibits PCSK9 to increase LDL receptor activity in the liver
